• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardlytics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    1/26/26 8:00:34 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email
    cdlx-20260123
    0001666071false00016660712026-01-232026-01-23

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): January 23, 2026
     
    cardlytics_logoa30.jpg
    CARDLYTICS, INC.
    (Exact Name of Registrant as Specified in its Charter)
    Delaware001-3838626-3039436
    (State or other jurisdiction of
    incorporation or organization)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
    675 Ponce de Leon Avenue NE, Suite 4100AtlantaGeorgia30308
    (Address of principal executive offices, including zip code)
    (888)798-5802
    (Registrant's telephone, including area code)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
    Title of each classTrading symbolName of each exchange on which registered
    Common StockCDLXThe Nasdaq Stock Market LLC
     Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



    Item 1.01 Entry into a Material Definitive Agreement.

    On January 23, 2026 (the “Signing Date”), Cardlytics, Inc. (the “Company”), PAR Technology Corporation (“PAR”) and DB Sub, LLC, an indirectly wholly owned subsidiary of PAR (“Buyer”), entered into an asset purchase agreement (the “Purchase Agreement”), pursuant to which Buyer agreed to acquire all of the Company’s assets, properties and rights primarily related to, or primarily used in, its Bridg platform (the “Purchased Assets” and the sale by the Company thereof, the “Bridg Sale”), subject to certain exceptions. In connection with the Bridg Sale, Buyer also agreed to assume certain liabilities and obligations of the Company arising out of the use, ownership, possession, operation or sale of the Purchased Assets. Other than the Purchased Assets, neither Buyer nor PAR will acquire any other assets of the Company pursuant to the Bridg Sale.

    Pursuant to the Purchase Agreement, and upon the terms and subject to the conditions thereof, as promptly as practicable after the closing of the Bridg Sale (the “Closing” and the date thereof, the “Closing Date”), but in any event on the Closing Date, PAR will deliver to the Company a number of shares of common stock of PAR (“PAR Common Stock”) equal to the quotient obtained by dividing (i) (A) $27,500,000 plus (B) an adjustment amount for certain new customer contracts entered into by the Company prior to Closing less (C) an estimated closing net adjustment amount for revenue received by the Company for goods or services to be delivered or performed after the Closing pursuant to contacts assigned to Buyer in connection with the Bridg Sale (provided, that, the number pursuant to this (i) shall not exceed $30,000,000) by (ii) the volume weighted average price of a share of PAR Common Stock on the New York Stock Exchange for the 15 consecutive trading days ending on the trading day immediately prior to (and excluding) the Closing Date as reported by Bloomberg, L.P. (“Purchase Consideration”). PAR has also agreed to use reasonable best efforts to promptly file a registration statement with the Securities and Exchange Commission (“SEC”) covering the resale of the shares of PAR Common Stock comprising the Purchase Consideration within three business days following the Closing Date, or, if later, PAR’s receipt of a completed investor questionnaire. PAR has also agreed to use commercially reasonable efforts to keep such registration statement effective until the earlier of the date that all such shares of PAR Common Stock have been sold or otherwise disposed of or can be sold without restriction pursuant to Rule 144 (or any successor thereof) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

    The Purchase Agreement contains customary representations, warranties, conditions and covenants of the Company, PAR and Buyer, including a non-competition and non-solicitation covenant for the Company with respect to the Purchased Assets for a period of five years following the Closing. Additionally, during the period from the Signing Date through and including the Closing Date, the Company has agreed to carry on its business with respect to the Purchased Assets in the ordinary course and consistent with past practices.

    The Closing is subject to the satisfaction or waiver of a number of customary closing conditions in the Purchase Agreement, including the absence of certain governmental restraints and the absence of a material adverse effect with respect to the Bridg platform or the Company’s ability to consummate the Bridg Sale.

    The Purchase Agreement may be terminated prior to the Closing by mutual written agreement of the Company and Buyer, or by either the Company or Buyer in certain circumstances specified in the Purchase Agreement, including by Buyer if any of the closing conditions specified in the Purchase Agreement have not been fulfilled by March 24, 2026, unless such failure is due to Buyer’s failure to perform or comply with any of the covenants, agreements or conditions required to be performed or complied with by Buyer prior to the Closing.

    The Purchase Agreement, the Bridg Sale and the other transactions contemplated by the Purchase Agreement have been approved by the board of directors of the Company.

    The foregoing is a summary description of certain terms of the Purchase Agreement, is not complete and is qualified in its entirety by reference to the text of the Purchase Agreement, a copy of which the Company expects to file as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.



    Cautionary Note Regarding Forward-Looking Statements

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this Current Report on Form 8-K other than statements of historical facts are “forward-looking statements”. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this Current Report on Form 8-K include statements regarding: the Company’s expectations and intentions regarding the completion of the Bridg Sale and the receipt of the Purchase Consideration. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of the companies may differ materially from the future results, performance and/or achievements expressed or implied by these forward-looking statements as a result of a number of factors. These factors include the satisfaction of closing conditions of the Bridg Sale. Uncertainties regarding technical difficulties, issues that might arise in any particular business relationship and other risks and uncertainties are set forth in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 5, 2025, and the Company’s other periodic reports that it files with the SEC from time to time. The statements made in this report are based on information available to the Company as of the date of this report and the Company undertakes no obligation to update any of the forward-looking statements after the date of this report.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     Cardlytics, Inc.
       
    Date:January 26, 2026By:/s/ Amit Gupta
      Amit Gupta
      
    Chief Executive Officer
    (Principal Executive Officer)


    Get the next $CDLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAR Technology to Acquire Bridg, Bringing Loyalty and Non‑Loyalty Data Together for Smarter Retail and Restaurant Activation

    Acquisition will accelerate PAR's roadmap for consumer data, loyalty, and media innovation PAR Technology Corporation (NYSE:PAR), a leading global foodservice technology provider, today announced that it has agreed to acquire the identity resolution and shopper intelligence platform Bridg, a division of Cardlytics, Inc. (NASDAQ Global Market: CDLX). The transaction is structured as an acquisition of substantially all Bridg assets. The purchase price is $27.5 million, subject to purchase price adjustments with a maximum total purchase price of $30.0 million, and is payable in shares of PAR Technology common stock. PAR Technology will also assume certain liabilities associated with the acqu

    1/26/26 8:02:00 AM ET
    $CDLX
    $PAR
    Computer Software: Programming Data Processing
    Technology
    Office Equipment/Supplies/Services
    Miscellaneous

    Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that on January 12, 2026, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 1,000,000 restricted stock units of Cardlytics to its newly appointed Chief Financial Officer, David Evans. The restricted stock units were granted as a material inducement to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). Half of the restricted stock units underlying the award shall vest on February 1, 2027, and the remaining 50% shall vest quarterly over the subsequent 12 months, subject to Evans' continuous

    1/16/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    SEC Filings

    View All

    Cardlytics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    1/26/26 8:00:34 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Cardlytics Inc.

    144 - Cardlytics, Inc. (0001666071) (Subject)

    1/5/26 4:23:23 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    12/18/25 8:00:14 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:46:37 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:45:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:39:19 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Cardlytics with a new price target

    Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

    10/11/24 8:36:58 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by Northland Capital with a new price target

    Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

    8/16/24 8:54:02 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

    8/15/24 7:18:52 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Evans David Thomas claimed ownership of 117,930 shares (SEC Form 3)

    3 - Cardlytics, Inc. (0001666071) (Issuer)

    1/16/26 4:51:29 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Chief Financial Officer Evans David Thomas

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    1/16/26 4:46:07 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer converted options into 12,788 shares and sold $7,316 worth of shares (6,253 units at $1.17), increasing direct ownership by 6% to 122,862 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    1/5/26 6:56:15 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Financials

    Live finance-specific insights

    View All

    Cardlytics Announces Third Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the third quarter ended September 30, 2025. "In Q3, we've taken decisive action that we believe will reset our business, improve our financial health, and set ourselves on a viable path to return to growth," said Amit Gupta, CEO of Cardlytics. "We are moving forward with sharper focus and discipline, prioritizing initiatives that build on our fundamental strengths and where we believe we can win. Our mandate is clear – continue to deliver for our partners and advertisers, strengthen what differentiates us, and unlock long-term value for our shareholders." Third Quarter 2025 Financial Results

    11/5/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Timing of Its Third Quarter 2025 Earnings Release

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the third quarter ending September 30, 2025 will be released on November 5, 2025, after market close. Conference Call Details: When: November 5, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 18219. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party

    10/22/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Second Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the second quarter ended June 30, 2025. "Building on the progress we've made over the past year, we are navigating headwinds by doubling down on our diversification efforts and reinforcing our unique network capabilities," said Amit Gupta, CEO of Cardlytics. "We believe our strategic shifts will position us for long-term profitable growth and enable us to deliver on the promise to our stakeholders." Second Quarter 2025 Financial Results Revenue was $63.2 million, a decrease of 9% year-over-year compared to $69.6 million in the second quarter of 2024. Billings, a non-GAAP metric, was $1

    8/6/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

    Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

    4/30/25 9:00:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    7/2/24 7:05:14 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/29/24 5:05:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/18/24 7:46:57 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology